Posted by Michael Wonder on 16 Dec 2021
FDA grants Calliditas Therapeutics accelerated approval of Tarpeyo (budesonide) to reduce proteinuria in IgA nephropathy
15 December 2021 - Tarpeyo (developed under the project name Nefecon) is the first and only FDA approved treatment that was specifically designed for this condition.
Calliditas Therapeutics today announced that the US FDA has approved Tarpeyo (budesonide) delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5g/g.
